Clinical trial NCT02968966: Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies
Official title: Pathophysiologie Basierte Therapie Von früh Beginnenden Epileptischen Enzephalopathien
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Seizure, Epileptic
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2016-11-21
Enrollment: 0
Sex: ALL
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Treatment A - if no positive response: Treatment B
Primary purpose: TREATMENT

Brief summary: Genetic epileptic encephalopathies (EEs) are a group of very rare and severe, pharmaco-resistant epilepsy forms characterized by an early onset, e.g. first years of life, and an often severe developmental delay. Genetic defects were found in different ion channels such as potassium or sodium channels explaining well the pathological neuronal hyperexcitability leading to seizures. Further mutations were also found in proteins relevant for cell structure, DNA/RNA processing or the synaptic vesicular metabolism. Specific and individualized therapies have not been established neither in the clinical routine nor in controlled studies. The goal of this monocentric non-blinded non-placebo controlled phase IIb study is the evaluation of the effectivity of anticonvulsive drugs specifically working on the ion channels defective in some subtypes of EEs in order to establish a standard and individualized therapy for these rare diseases based on the specific genetic defect.

Detailed description: During the study, the sodium channel blockers phenytoin and lacosamide and the potassium channel blocker kinidinsulfate will be given under standardized conditions to patients with an early onset and pharmaco-resistant genetic epilepsy with and without mutations in the potassium channels KCNT1 and KCNQ2 and the sodium channel gene SCN2A. The primary endpoint will be a significant seizure reduction under trial medication compared to baseline. Secondary endpoints will be the improvement of electroencephalographic characteristics of the respective EEs.

Eligibility criteria: Inclusion Criteria:

* highly active epilepsy (≥ 1 seizure per day)
* epilepsy with onset 0-3 months of age
* pharmaco-resistant epilepsy (2 or more standard anticonvulsive medications tried before)
* recently max. two stable anticonvulsive drugs for minimum 4 days before study start
* patients under continuous monitoring control
* patients younger than 1 year of age

Exclusion Criteria:

* high grade cardial rhythm disorders
* severe liver, renal and electrolyte blood parameter changes
* metabolic or lesional origin of epilepsy (metabolic screening results and cranial MRI available)
* parallel participation in other studies (must be finished two month before study start)
* missing informed consent

Primary outcomes:
measure: Reduction of seizures
timeFrame: one week
Secondary outcomes:
measure: Reduction of seizures stratified for genetic background
timeFrame: one week
measure: Reduction of epileptic activities or suppression phases
timeFrame: one week
Other outcomes:
Locations:
city: Tübingen
country: Germany
facility: Universtiy Hospital
Study officials:
affiliation: University Children's Hospital Tübingen
name: Markus Wolff, Dr.
role: PRINCIPAL_INVESTIGATOR
References: